Adalimumab for the treatment of adults with psoriasis

  • Technology appraisal guidance
  • TA146
  • Published: 
Download guidance (PDF)

8 Sources of evidence considered by the Committee

The Evidence Review Group (ERG) report for this appraisal was prepared by Southampton Health Technology Assessments Centre (SHTAC), University of Southampton:

  • Turner D, Picot J, Cooper K et al. Adalimumab for the treatment of psoriasis, November 2007.

The following organisations accepted the invitation to participate in this appraisal. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). The manufacturer or sponsor, and professional, specialist, patient and carer groups were also invited to make written submissions. The professional, specialist, patient and carer groups had the opportunity to give their expert views on adalimumab by providing a written statement to the Committee. The manufacturer or sponsor, and professional, specialist, patient and carer groups, and other consultees have the opportunity to appeal against the final appraisal determination.

Manufacturer or sponsor:

  • Abbott Laboratories Limited

Professional, specialist, patient and carer groups:

  • Psoriasis and Psoriatic Arthritis Alliance

  • Psoriasis Association

  • British Association of Dermatologists

  • Royal College of Nursing

  • Royal College of Physicians

Other consultees:

  • Nottinghamshire PCT

  • Department of Health

  • Welsh Assembly Government

Commentator organisations (did not provide written evidence and without the right of appeal):

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • NHS Quality Improvement Scotland

  • Novartis Pharmaceuticals UK Limited

  • Pfizer

  • MerckSerono Limited

  • Wyeth Pharmaceuticals

The following individuals were selected from clinical specialist and patient advocate nominations from the non-manufacturer or sponsor consultees and commentators. They gave their expert personal view on adalimumab by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Professor Christopher Griffiths, Professor of Dermatology, Head of The Dermatology Centre and Division of Medicine and Neurosciences, University of Manchester. Nominated by Royal College of Physicians – clinical specialist

  • Professor Jonathan Barker Professor of Consultant Dermatologist, Head of Psoriasis Unit, St John's Institute of Dermatology. Nominated by the British Association of Dermatologists – clinical specialist

  • Mr Ray Jobling, Chairman of the Psoriasis Association. Nominated by the Psoriasis Association – patient expert

  • Mr David Chandler. Nominated by the Psoriasis and Psoriatic Arthritis Alliance – patient expert

ISBN: 978-1-4731-6646-2